文献速递心力衰竭与心肌病血脂与心血管预防

钠-葡萄糖协同转运蛋白2抑制剂在心力衰竭中的作用机制

Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure.
PubMed 文献 · Heart · 2021-06-11

2型糖尿病患者心力衰竭风险高于健康人群,SGLT2抑制剂在临床试验中改善血糖并减少心血管事件和心衰住院,且无糖尿病的心衰患者也获益,但机制未明。本文综述了心肌细胞钙处理、能量代谢、自噬和心外膜脂肪等心脏特异性机制。

要点

  • SGLT2抑制剂在有无糖尿病的心衰患者中均减少心衰住院。
  • 降糖、利尿、减重和降压不能完全解释临床获益。
  • 新机制包括改善心肌钙处理、能量代谢、诱导自噬和减少心外膜脂肪。

核心结论

  • SGLT2抑制剂的心脏获益机制尚未完全阐明,可能涉及心肌细胞钙处理、能量代谢、自噬和心外膜脂肪等多条通路。

研究设计与样本

  • 本文为叙述性综述,总结SGLT2抑制剂在心力衰竭中作用机制的最新证据及进行中的相关研究。

主要发现

  • 2型糖尿病患者心衰风险高于健康人群。
  • SGLT2抑制剂改善血糖控制并减少2型糖尿病患者的心血管事件和心衰住院。
  • 无2型糖尿病的心衰患者也观察到临床获益。
  • 降糖、利尿、减重和降压等机制不能完全解释观察到的临床结局改善。
  • 新提出的机制包括改善心肌细胞钙处理、增强心肌能量代谢、诱导自噬和减少心外膜脂肪。

临床怎么用

  • 临床医生应了解SGLT2抑制剂的心衰获益不依赖于降糖作用,其机制涉及多种心脏特异性通路。

局限性

  • SGLT2抑制剂在心力衰竭中获益的确切机制尚未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with type 2 diabetes mellitus are at a higher risk of developing heart failure compared with the healthy population. In recent landmark clinical trials, sodium-glucose co-transporter 2 (SGLT2) inhibitor therapies improve blood glucose control and also reduce cardiovascular events and heart failure hospitalisations in patients with type 2 diabetes. Intriguingly, such clinical benefits have also been seen in patients with heart failure in the absence of type 2 diabetes although the underlying mechanisms are not clearly understood. Potential pathways include improved glycaemic control, diuresis, weight reduction and reduction in blood pressure, but none fully explain the observed improvements in clinical outcomes. More recently, novel mechanisms have been proposed to explain these benefits that include improved cardiomyocyte calcium handling, enhanced myocardial energetics, induced autophagy and reduced epicardial fat. We provide an up-to-date review of cardiac-specific SGLT2 inhibitor-mediated mechanisms and highlight studies currently underway investigating some of the proposed mechanisms of action in cardiovascular health and disease.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Joshi SS, Singh T, Newby DE, et al. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart. 2021. PMID: 33637556. doi:10.1136/heartjnl-2020-318060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。